Compare LARK & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | BNR |
|---|---|---|
| Founded | 1885 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 179.7M |
| IPO Year | 2001 | 2019 |
| Metric | LARK | BNR |
|---|---|---|
| Price | $28.56 | $9.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.4K | ★ 14.5K |
| Earning Date | 04-29-2026 | 06-05-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.43 | $2.95 |
| 52 Week High | $30.80 | $41.72 |
| Indicator | LARK | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 26.83 |
| Support Level | $25.46 | $7.99 |
| Resistance Level | $29.46 | $9.70 |
| Average True Range (ATR) | 0.77 | 1.19 |
| MACD | 0.02 | -0.50 |
| Stochastic Oscillator | 86.62 | 6.87 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.